PrP C -deficient mice expressing prion protein variants with large amino-proximal deletions (termed PrP DF ) suffer from neurodegeneration, which is rescued by full-length PrP C . We now report that expression of PrP DCD , a PrP variant lacking 40 central residues (94-134), induces a rapidly progressive, lethal phenotype with extensive central and peripheral myelin degeneration. This phenotype was rescued dose-dependently by coexpression of full-length PrP C or PrP C lacking all octarepeats. Expression of a PrP C variant lacking eight residues (114-121) was innocuous in the presence or absence of full-length PrP C , yet enhanced the toxicity of PrP DCD and diminished that of PrP DF . Therefore, deletion of the entire central domain generates a strong recessive-negative mutant of PrP C , whereas removal of residues 114-121 creates a partial agonist with context-dependent action. These findings suggest that myelin integrity is maintained by a constitutively active neurotrophic protein complex involving PrP C , whose effector domain encompasses residues 94-134.
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Introduction
PrP Sc is the only known constituent of mammalian prions (Prusiner, 1982) , the infectious agents causing transmissible spongiform encephalopathies. PrP
Sc is an isoform of the cellular prion protein PrP C (Oesch et al, 1985) , which is expressed in a broad range of vertebrate tissues (Bendheim et al, 1992) . PrP C is secreted into the endoplasmic reticulum and processed by removal of its amino-terminal signal peptide, N-linked glycosylation at two sites, and replacement of its carboxy-terminal tail by a glycosyl phosphatidyl inositol (GPI) group, which anchors it to the cell surface. Ablation of Prnp, the gene encoding PrP C , abrogates prion replication (Bueler et al, 1993) and scrapie pathogenesis .
The physiological function of PrP C is unclear (Aguzzi and Polymenidou, 2004) . Prnp o/o mice enjoy a normal life expectancy (Bueler et al, 1992) . Changes in circadian rhythms, alterations of hippocampal function, and behavioral abnormalities were reported in Prnp o/o mice, but their molecular basis has not been clarified. PrP C may have antiapoptotic (Kuwahara et al, 1999; Bounhar et al, 2001; Chiarini et al, 2002; Zanata et al, 2002) or proapoptotic properties (Paitel et al, 2002 (Paitel et al, , 2003 (Paitel et al, , 2004 . A possible superoxide dismutase activity of PrP C (Brown et al, 1997) has not been confirmed in vivo (Hutter et al, 2003) . Unsurprisingly, a unified view of the above observations is still missing.
Transgenic expression of PrP variants carrying aminoproximal interstitial deletions (D32-121, termed PrP DE , and D32-134, termed PrP DF ) causes ataxia, progressive cerebellar granule cell degeneration, leukoencephalopathy, and death of Prnp o/o mice at 3-4 months of age (Shmerling et al, 1998; Radovanovic et al, 2005) . Toxicity was associated only with PrP versions whose deletions extended into the highly conserved hydrophobic core (HC) domain , which is situated between the flexible amino-proximal tail of PrP C and its globular carboxy-proximal domain (Wuthrich and Riek, 2001) . A similar phenotype was detected in mice overexpressing Dpl (Moore et al, 1999; Weissmann and Aguzzi, 1999; Rossi et al, 2001) , whose structure resembles that of PrP DF . In each case, the pathological phenotype was rescued by substoichiometric coexpression of full-length PrP C , either from the endogenous Prnp locus or as a transgene driven by various promoters. Those results suggested that PrP DF and Dpl interfere with a physiological function of PrP C in the brain.
PrP DF lacks the octarepeat region (OR) and a central domain (CD) that comprises a charge cluster (CC, residues 95-110) and a hydrophobic core (HC, residues 112-134) ( Figure 1A and B). To analyze the relative contribution of these domains to the phenotype, we generated Prnp transgenes lacking the entire CD (henceforth termed PrP DCD ) or part of the HC domain (termed PrP DpHC ). Whereas PrP DpHC was innocuous even in the absence of full-length PrP C , expression of PrP DCD caused a drastic neuropathological phenotype and death within 20-30 days. This phenotype was partially counteracted by high levels of PrP C and, to a lesser extent, by a PrP mutant lacking the octarepeats. While PrP DpHC behaved neutrally in the absence of PrP C , it partially rescued the toxic effects of PrP DF , whereas it accentuated those of PrP DCD .
Results

Characterization of interstitially deleted PrP species in transgenic mice
All PrP mutants described below are based on the 'halfgenomic' pPrPHG backbone containing a redacted murine Prnp gene from which intron #2 was deleted, and flanked by 6 and 2.2 kb of 5 0 and 3 0 genomic regions, respectively (Borchelt et al, 1996; Fischer et al, 1996) . PrP DC lacks residues 32-93 within the OR region, and PrP DC mice do not display any pathological phenotype (Shmerling et al, 1998) . The deletions in PrP DE and PrP DF extend into the HC domain (aa 32-121 and 32-134; Figure 1A and B) and induce neuropathological lesions in Prnp o/o mice. These lesions may be caused by the ablation of CD, by the combined ablation of octarepeat and CD, or by the disruption of HC. We tested these alternatives by creating additional PrP mutants with interstitial deletions of amino acids 94-134 (termed PrP DCD ) and 114-121 (termed PrP DpHC ; Figure 1B Figure 1D ) and protein expression (Figure 2) .
In all transgenic lines, brain expression of PrP mutants was lower than that of endogenous PrP C ( Figure 2C ) and paralleled the number of integrated transgenic copies. Tg1046 PrP DCD and Tg902 PrP DpHC expressed o20% of Prnp þ /o , whereas Tg1047, Tg1048, and Tg1050 expressed ca. 35, 80, and 75% of Prnp þ /o , respectively ( Figure 2D ). The anatomical distribution of the transgenic proteins resembled that of PrP DF ( T g 1 0 4 7 P r n p + /+ T g 9 0 2 P r n p o /o P r n p + /+ P r n p + /+ D N a s e c o n t . ( Figure 2A ), suggesting that each protein was N-glycosylated to a similar extent. PrP C displayed a significant amount of C1 fragment (Figure 2A , arrowhead), yet C1 formation was reduced in PrP DpHC and absent from PrP DCD , suggesting abnormal endoproteolysis of these proteins. We then analyzed detergent-resistant membranes from PrP C , PrP DCD , and PrP DpHC brains by step density-gradient centrifugation. The buoyancy of PrP DCD and PrP DpHC was similar to that of PrP C and flotillin ( Figure 2B ), suggesting that they all reside in similar membrane microdomains. Therefore, most aspects of PrP DCD and PrP DpHC biogenesis appear similar to those of PrP C .
Pathological phenotypes of mice expressing interstitially deleted PrP species
All PrP DCD transgenic lines (Tg1046, Tg1047, Tg1048, and Tg1050) were maintained in the Prnp þ / þ background.
Founders Tg1046, Tg1047, and Tg1050 remained healthy, whereas founder Tg1048, which displayed the highest expression of the transgene, developed behavioral abnormalities at 120 days of age (Supplementary movie). However, its entire transgenic PrP DCD þ /o offspring died at 20 days of age. As incipient paraparesis of founder Tg1048 precluded natural breeding, sperm was used for in vitro fertilization of Prnp C57BL/6 oocytes. This resulted in a total of 117 Prnp þ / þ pups, of which 46 carried the PrP DCD transgene. The gender distribution of pups was mendelian (58 #; 59~), but transgenic males were marginally underrepresented (17 #; 29~; w 2 Po0.03). By 50 days of age, all (46/46) Tg1048 PrP DCD þ / þ animals had developed ataxia, which progressed over 20-30 days, eventually leading to the inability to stride on cage grids. By the age of 80 days, 40/46 animals had developed spastic paraparesis, which by 95 days progressed to full paraplegia. A four-degree clinical score was developed for monitoring and animal welfare purposes (Table I) . Mice were euthanized within 3 days of reaching a score of 3.5, or within 1 day of developing a score of 4 ( Figure 3E and Supplementary Figure 1) . By the age of 99 days all 46 animals had to be euthanized ( Figure 3A ). All transgenic Tg1050 PrP DCD þ / þ mice developed a disease similar to that of Tg1048, but progression was slower. First signs became noticeable at 110 days and progressed to terminal disease at 160 days ( Figure 3B ). Tg1046 and Tg1047 PrP DCD þ / þ mice, which expressed lower levels of transgenic protein, did not experience spontaneous disease before 450 days of age.
Genetic interactions between PrP C and mutated PrP
In order to probe genetic interaction between PrP DCD and PrP Figure 3C ) and were consistently underweight despite facilitated access to food and water ( Figure 3F ). Only 20% of Tg1046 PrP DCD þ /o offspring developed disease within 500 days ( Figure 3D ), yet PrP DCD o/o mice developed clinical signs at 17-21 days and progressed to terminal disease by 23-28 days. The most dramatic phenotype was seen in Tg1050 PrP DCD o/o mice, which developed perinatal ataxia and terminal disease before 10 days of age ( Figure 3B ). We conclude that reduction or removal of PrP C results in greatly exacerbated phenotypes. We then tested whether overexpression of PrP C antagonizes PrP DCD toxicity. We crossed Tg1050 PrP DCD o/o to tga20 mice, which overexpress PrP C six-fold. In order to circumvent the early lethality of Tg1050 PrP DCD o/o mice, we first introduced the tga20 allele into PrP DCD þ / þ mice and subsequently removed Figure 3B) . Therefore, the severity of the disease is attenuated by overexpression of PrP C ( Figure 3G ). As these phenomena were confirmed in four independently generated lines of transgenic mice, we conclude that both the PrP Cdependent attenuation and the Prnp o -dependent exacerbation of the phenotype are independent of the site of transgene integration.
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Neuropathological changes
Histological examination of the brains from terminally sick Tg1047 PrP DCD þ /o mice revealed vacuolar degeneration and astrogliosis of several white matter tracts, most pronouncedly in the internal capsule and the pyramidal tracts ( Figure 4B ), the white matter areas of the brainstem, and, to a lesser degree, in the cerebellum. No degeneration, however, was present in the cerebellar cortex including the cerebellar granule cell layer ( Figure 4D ). There were no changes in the cerebral cortex or in the basal ganglia. No changes were found in age-matched non-transgenic littermates ( Figure 4A and C). Coarse vacuolar degeneration was found in both descending and ascending fiber tracts of the spinal cord (Figure 4E and G) . In contrast to non-transgenic Prnp þ /o littermates ( Figure 4F and H), myelinated fiber tracts in the spinal cord displayed axonal loss, which was associated with enlarged degenerating fibers with thinning of their myelin sheaths ( Figure 4I ). There was no onion bulb formation. Evidence for degeneration of myelinated fibers, including axonal breakdown and segmentation of myelin into ellipsoids ('digestion chambers'), was obtained in the sciatic nerve ( Figure 4K ). Analysis of semithin sections revealed axonal loss, enlarged 'vacuolated' fibers, as well as degenerating myelinated fibers ( Figure 4M ). No such changes were found in sciatic nerves from control littermates ( Figure 4J and L). Electron microscopy revealed axonal breakdown and hypomyelinated fibers, as well as demyelinated fibers and myelin-digesting macrophages ( Figure 4N -P). These findings are indicative of widespread axomyelinic degeneration with minor neuronal degeneration. Because axons build functional units with their myelin sheaths, and both compartments underwent degeneration, it is difficult to establish whether primary damage was to axons or to myelin sheaths. We proposed earlier that myelin toxicity is the primary cause of damage, as the white (Radovanovic et al, 2005) . Direct comparisons showed similar myelin damage in PrP DCD and PrP DF mice. However, PrP DCD mice lacked the extensive cerebellar granule cell degeneration found in PrP DF mice (Shmerling et al, 1998; Radovanovic et al, 2005) . Myelin damage in Prnp Nsk/Nsk and Prnp o/o mice was associated with concentric 'onion bulb' figures indicative of multiple episodes of demyelination and remyelination, which was not a feature in PrP DCD mice. The latter discrepancy may be related to the higher toxicity of PrP DCD , which may preclude reparative remyelination. neurological disease starting at 70 days of age (n ¼ 9), and by 300 days 50% had reached a clinical score of X3.5 ( Figure 5A ). When PrP DCD and PrP DF were coexpressed in the presence of diploid Prnp (PrP DCDDF þ / þ ), only two of six aged mice developed disease ( Figure 5A ). We conclude that neither PrP DF nor PrP DCD antagonizes the toxicity of each other. This reinforces the suggestion that PrP DF and PrP DCD compete with PrP C by the same molecular mechanism. Interestingly, PrP DCD fully imposed its phenotype onto PrP DCDDF mice, although PrP DF was much more abundant than PrP DCD ( Figure 5E ).
Genetic interactions between PrP
Tg1047 or Tg1050 PrP DCD þ / þ mice were then mated to PrP DC mice, which express a PrP mutant devoid of all ORs (line TgC4; Shmerling et al, 1998) . The longevity of PrP DCDDC þ /o offspring (n ¼ 37) was 290 and 120 days of age, respectively, which is three-fold more than PrP DCD þ /o mice from the same lines (n ¼ 22; Figure 5B ). As PrP DC does not contain any OR, we conclude that the rescuing ability of PrP C does not require this structural motif, as was shown in coexpression experiments of PrP DC and PrP DF (Flechsig et al, 2000; Flechsig and Weissmann, 2004) . PrP DC expression was higher than that of PrP C and PrP DCD (Figure 5F ), suggesting that the rescuing potency of PrP C was lower than that of PrP Figure 4 White matter pathology and peripheral neuropathy in terminally sick PrP DCD mice. Age-matched non-transgenic Prnp þ / þ littermates served as controls for all histological investigations. GFAP-stained pyramidal tract showed vacuolar degeneration and associated astrogliosis in a sick PrP DCD mouse (B) but not in a control mouse (A). GFAP-stained cerebellum in PrP DCD mice revealed moderate astrogliosis but preserved cerebellar granule cell layer (D). The same region in an age-matched control littermate (C). Luxol-Nissl-stained cross-section through the midthoracic spinal cord showed coarse vacuolar degeneration in descending and ascending fiber tracts (E, G). No such changes were observed in control mice (F). Paraphenylene diamine-stained semithin section of a descending myelinated fiber tract in a PrP DCD mouse revealed axonal loss together with some enlarged 'vacuolated' myelinated fibers with thinning of their myelin sheaths (asterisk) (I). Age-matched control littermate (H). Luxol-Nissl-stained longitudinal section through the sciatic nerve of a control (J) and a PrP DCD mouse (K). Axonal breakdown and segmentation of myelin into digestion chambers (arrows). Axonal loss, hypomyelinated fibers, and degeneration of myelinated fibers with collapsed myelin sheaths (arrow) were observed in paraphenylene diamine-stained semithin sections of the sciatic nerve in PrP DCD mice (M) but not in control mice (L). Electron microscopic analysis of the sciatic nerve showed demyelinated fibers (N) associated with macrophages filled with myelin debris (O). Some fibers showed collapsed axons surrounded by abnormal condensed multilamellar myelin sheaths (P). Normal myelinated fibers in a control mouse (Q). Scale bar: (A-E) 100 mm; (F, G, J, K) 20 mm; (H, I, L, M) 10 mm; (N-Q) 2 mm. 
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Discussion
We found that prion proteins lacking solely a highly conserved sequence of 40 amino acids (the 'central domain', CD) are potent neurotoxins. In the absence of full-length PrP C , even small amounts of PrP DCD induce early postnatal death. Toxicity was strictly dose-dependent, with doubling of expression resulting in a decrease of longevity by 10 days ( Figures 2D and 3A-D) .
The clinical signs of PrP DCD mice were associated with widespread central and peripheral neuropathy similar to mice overexpressing Dpl or PrP DF (Shmerling et al, 1998; Rossi et al, 2001 ). Myelin damage, rather than neuronal loss, was the primary cause of lethality in these mice (Radovanovic et al, 2005) . A similar, but milder, myelin phenotype was described in aged Zrch-I Prnp o/o mice (Nishida et al, 1999) . Therefore, rather than inducing an entirely artificial disease, PrP DCD , PrP DE , PrP DF , and Dpl appear to greatly aggravate a pathology caused by a defect in PrP C function. This intriguing observation suggests that maintenance of myelin integrity represents a major physiological role of PrP C . What may be the mechanism of PrP DCD neurotoxicity? Any interstitial deletions may destabilize proteins, resulting in cytotoxicity. However, as most of the CD domain is intrinsically unstructured, its deletion is unlikely to dramatically destabilize PrP. Secondly, toxicity may result from subcellular mislocalization (Kaneko et al, 1997; Ma et al, 2002) or inappropriate membrane topology of PrP (Hegde et al, 1998) . However, these scenarios are unlikely as (1) PrP DCD undergoes glycosylation, processing, and transport to detergent-resistant membrane microdomains, similar to full-length PrP, and (2) full-length PrP C does not antagonize the toxicity of cytosolic PrP .
We tested whether the DCD, DE, and DF deletions increase the aggregation propensity of PrP C . This is unlikely, as PrP DCD was fully sensitive to proteinase K digestion and did not form immunohistochemically detectable aggregates in transgenic mice (data not shown). Finally, formation of the carboxyproximal C1 fragment of PrP was significantly impaired in PrP DCD mice, suggesting abnormal endoproteolysis of PrP DCD . Although the molecular basis of this phenomenon is unclear, it is unlikely to account for toxicity, as healthy PrP DpHC mice also displayed a similarly reduced C1 fragment.
The pathogenetic mechanisms of many human hereditary diseases, as well as many bacterial toxins, include inappropriate signaling events. As PrP C may transduce signals (Mouillet-Richard et al, 2000; Mattei et al, 2004; Solforosi et al, 2004) , the neurotoxicity of PrP mutants may rely on similar mechanisms. The pathological phenotype of PrP DCD , PrP DE , and PrP DF mice was counteracted by overexpression of full-length PrP C (Shmerling et al, 1998) and exacerbated by removal of the endogenous Prnp gene, suggesting that PrP DCD , PrP DE , and PrP DF compete with PrP C for a common signaling molecule. This suggestion is strengthened by crossing experiments showing that neither mutant protein ameliorates the phenotype induced by the other. The phenotype was solely determined by the stoichiometric ratio of full-length versus redacted PrP, regardless of whether PrP C was expressed from its endogenous Prnp locus or as a transgene.
All toxic mutants displayed disruption of the charge cluster (CC, residues 95-110) and a part of the hydrophobic core (HC, residues 111-121) of PrP C . Toxicity was ameliorated by coexpressing PrP variants with intact CC and HC, even if these variants-as in the case of PrP DC -lacked the OR. We therefore posit that PrP C exerts a myelin-maintaining activity by signaling through the CD domain to an unknown receptor (tentatively termed PrP R ). In all paradigms investigated, the phenotype was determined by the stoichiometry of mutant to full-length PrP, strongly suggesting that PrP C , the various mutant PrP moieties, and PrP R form hetero-oligomeric complexes ( Figure 6 ). The mild pathological phenotype of Prnp o/o mice suggests that myelin integrity is supported by residual PrP R activity, whereas disruption of the CD domain sequesters PrP R in a dominant-negative state. Complex stability could be influenced by domains distinct from those involved in executing signal transduction: the context-dependent toxicity of PrP DpHC implicates the OR as one such domain ( Figure 6 ). Although deletion of 40 amino acids produced a powerfully toxic molecule, ablation of eight amino acids within this domain (PrP DpHC ) was innocuous to both wildtype and Prnp o/o mice. Crossing experiments show that PrP DpHC is not functionally equivalent to PrP C . The toxicity of PrP DF was diminished, yet that of PrP DCD was augmented by coexpression of PrP DpHC . In the frame of the signaling model, the deletion in PrP DpHC may affect the interaction between PrP C and PrP R . Verification of the model presented above requires the physical identification of PrP R . Towards that goal, it will be crucial to enumerate the cellular constituents-which may not necessarily all consist of protein-binding differentially to PrP C and to the various mutants described here. Functional assays of such constituents may finally shed light on the physiological function of the prion protein, and may eventually help understanding neurodegeneration in transmissible spongiform encephalopathies.
Materials and methods
Construction of transgenes
The coding sequence of the murine Prnp gene was analyzed using DNAMAN software (Lynnon BioSoft, Canada) and a hydrophobicity plot was generated using a window of nine amino-acid residues. The regions identified in this plot were used to define the CC, CD, and HC domains. Based on pPrPHG , a PmeI/ NheI subclone was generated in the pMECA backbone. (2) PCR fragments with primer sets RAMP fw (5 0 -CTA TCA GTC ATC ATG GCG AAC C)/RAMP 93 ex-rc (5 0 -CCA AAA TGG ATC ATG GGC CTA CCC CCT CCT TGG CCC CAT C) and RAMP 93-134 fw (5 0 -GAT GGG GCC AAG GAG GGG GTA GGC CCA TGA TCC ATT TTG G)/ RAMP rc (5 0 -CAT CAT CTT CAC ATC GGT CTC G). The resulting PCR products were purified, mixed in stoichiometric amounts, and annealed by slowly decreasing the temperature from 95 to 401C. The flanking primers RAMP fw and RAMP rc were then added and the fusion product was amplified. This product was purified, digested with XmaI/BstEII, and cloned into the respective sites of the pMECA PrP subcloning vector. The subcloned construct was then cloned into the PmeI/NheI sites of the pPrPHG plasmid. Plasmid MoPrP-DH1 coding for PrP DpHC was constructed by inserting the cDNA encoding moPrPD114-121, recovered from plasmid pUC-PrPD114-121 (Holscher et al, 1998) by restriction with AatII and SacI, followed by blunting into plasmid MoPrP.XhoI, a derivative of pPrPHG (Borchelt et al, 1996; Fischer et al, 1996) upon restriction with XhoI and blunting.
Generation, identification, and maintenance of transgenic mice For construction of PrP DCD and PrP pHC , the pPrPHG plasmids containing the PrP coding sequences were propagated in Escherichia coli XL1 blue, the minigene excised with NotI and SalI, processed as described , and injected into fertilized Prnp
oocytes (C57BL/6 Â DBA/2 cross and C3H Â C57BL6) by standard procedures (Rulicke, 2004) . Transgenes on a Prnp o/o background were identified by PCR using the exon 2 primer pE2 þ (5-CAA CCG AGC TGA AGC ATT CTG CCT) and the exon 3 primer Mut217 (5-CCT GGG ACT CCT TCT GGT ACC GGG TGA CGC). In order to outbreed the Prnp þ allele, PCR analysis was carried out using primers P10 ( 
Southern blot analysis
Mouse tail biopsies were kept on ice and digested in lysis buffer (100 mM Tris-HCl (pH 8.5), 5 mM EDTA, 0.2% SDS, 20 mM NaCl, and 100 mg/ml Proteinase K) overnight at 551C under constant agitation. Purified genomic DNA (20 mg) was digested overnight (EcoRI, 100 U and separated on 0.7% agarose gels (GIBCO BRL ultra Pure agarose). Completeness of the restriction digest and DNA separation was checked by ethidium bromide staining. Genomic DNA was transferred by vacuum blotting at 50-55 mbar with a Vacu Gene Pump and a Gene XL blotting apparatus (Pharmacia) using solutions according to the manufacturer's manual (Pharmacia). The blot was marked, washed for 5 min in 2 Â SSC, UV-crosslinked and prehybridized according to Church and Gilbert (1984) . After hybridization (overnight at 651C) with a radioactively labeled probe (PrP open reading frame), the blot was washed and membranes were subjected to autoradiography using a PhosphoImager (Molecular Dynamics). Images were scanned and signals were quantified with Aida 2.41 imaging software. For probe labeling, template DNA (50 ng) was diluted in sterile water and random primers (nonamers or hexamers) were added (Prime-IT s II; Random Primer labeling kit cat# 300385; Stratagene). After gentle mixing, incubation was performed at 951C for 5min. Brief centrifugation was followed by 3 min incubation on ice. This was followed by addition of 5 Â primer buffer (ÀdCTP), radioactively labeled [a
À32
]P-dCTP (corresponding to 25 mCi; Amersham Biosciences), and Klenow 5 U/ml (Prime-IT s II; Random Primer labeling kit cat# 300385). For primer elongation, the probe was incubated at 371C for 75 min. For purification, the QIAquick PCR purification kit was used according to the manufacturer's manual (Quiagen). mRNA analysis Total brain RNA was isolated in Trizol (Life Technologies), purified, and DNase-treated according to the manufacturer's manual (Roche). After reverse transcription (Geneamp; Roche), cDNA was used for PCR using primers Taq5 0 PrPa (5 0 -CAA CCG AGC TGA AGC ATT CTG CCT) and Taq3 0 PrPa (5 0 -GAT CTT CTC CCG TCG TAA T). As control for the PCR procedure and possible DNA contamination, DNase-treated RNA from wild type and transgenic mice that had not been reversely transcribed was used.
Western blot analysis
Brain hemispheres were homogenized in 7 vol PBS, 0.5% Nonidet P-40, and 0.5% deoxycholate and the solution was centrifuged for 5 min in an Eppendorf centrifuge. For deglycosylation, up to 50 mg of denatured total protein was incubated at 371C for 4 h with 500 U PNGase F (New England Biolabs) according to the manufacturer's instructions. The protease inhibitors Pefabloc (1 mg/ml), leupeptin (10 mg/ml), pepstatin (10 mg/ml), aprotinin (1 mg/ml) (all from Boehringer, Mannheim), and 0.5 mg/ml EDTA were added. After electrophoresis of protein samples through 12% SDS-polyacrylamide gels, samples were transferred to nitrocellulose membranes (Schleicher & Schuell) and incubated with mouse monoclonal antiPrP antibodies POM1, POM3, and POM11 (Polymenidou et al, 2005) , followed by incubation with peroxidase-labeled anti-mouse antiserum (1:2500; Amersham) and developed with the ECL detection system (Pierce). Antibody incubations were performed in 1% Top Block (Juro) in Tris-buffered saline-Tween (TBS-T) for 1 h at room temperature or overnight at 41C.
Flotation assays
Flotation of detergent insoluble complexes was performed as described (Naslavsky et al, 1997) . Appropriate brain homogenates were extracted for 2 h on ice in cold lysis buffer (150 mM NaCl, 25 mM Tris-HCl, pH 7.5, 5 mM EDTA, 1% Triton X-100; total protein: 1 mg in 1.6 ml). Extracts were mixed with two volumes (3.2 ml) of 60% Optiprep (Nycomed) to reach a final concentration of 40%. All lysates were loaded at the bottom of Beckman ultracentrifuge tubes. A 5-30% Optiprep s step gradient in TNE (150 mM NaCl, 25 mM Tris-HCl, pH 7.5, 5 mM EDTA) was then overlaid onto the lysate (8.4 ml of 30% Optiprep s and 3.6 ml of 5% Optiprep s ). Tubes were centrifuged for 24 h at 41C in a TLS55 Beckman rotor at 100 000 g. Fractions (1 ml) were collected from the top of the tube and processed for immunoblotting and visualization with anti-PrP antibody POM1 (Polymenidou et al, 2005) , antiflotillin 1, and anti-GAPDH antibody (both from BD Transduction Laboratories).
Clinical scoring and observation
Mice were examined once weekly for clinical signs, including weight loss, kyphosis, rough hair coat, paresis, ataxia, and decreased motor activity. In addition, mice were placed on a metal grid and monitored for 5 min for their walking proficiency. The incidence of slipping between bars was assessed and integrated with all parameters mentioned above into a clinical score (Table I) . Mice were euthanized when they reached a score of 3.5 or higher. Statistical significance was assessed using Mann-Whitney test.
Morphological analysis
Brains, spinal cords, and sciatic nerves were removed and fixed in 4% formaldehyde in PBS, pH 7.5, paraffin embedded, and cut into 2-4 mm sections. Sections were stained with hematoxylin and eosin (H&E), Luxol-Nissl (myelin and neurons), and commercial antibodies to GFAP (glial fibrillary acidic protein; activated astrocytes), MBP (myelin basic protein), NF200 (neurofilament 200), IBA1 (microglia), SAF84 (PrP Sc aggregates), and POM1 (soluble cellular PrP). For semi-thin sections and electron microscopy, mice were perfused with ice-cold 4% PFA/2% glutaraldehyde. Spinal cord and sciatic nerve tissues were removed, immersed in the same solutions, and kept at 41C until processing. Tissues were embedded in Epon, and semi-thin sections were stained with toluidine blue and paraphenylene diamine or used for electron microscopy.
